Glaukos touts IOP reduction in pseudophakic iStent study

Glaukos (NYSE:GKOS) today released data from a study of its iStent trabecular micro-bypass stent, touting reduced intraocular pressure when implanted in pseudophakic eyes with open-angle glaucoma. Data from the study was recently published in the Journal of Glaucoma, the Laguna Hills, Calif.-based company said. Glaukos’ iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted into multiple trabecular meshwork through a single corneal entry point to reduce IOP, the company said. Pseudophakic eyes are eyes in which the natural lens has been removed and replaced with an intraocular lens. Data from the retrospective, consecutive case series explored outcomes in 42 procedures in which the iStent device was implanted in pseudophakic eyes with preoperative mean intraocular pressures of 20.26 mm Hg. After 2 years, 21 eyes treated with the iStent reported a mean medicated IOP decrease of 6.64 mm Hg, down 33% A total 96% of patients with preoperative medicated IOP of greater than or equal to 19 mm Hg reported a reduction in IOP on their last follow-up. Only 1 patient required additional glaucoma surgery, Glaukos said, commenting that the “safety profile was favorable.” “While multiple studies and years of real-world experience have demonstrated the ability of iStent to achieve sustained IOP reductions when used in combination with cataract surgery, we wanted to explore the IOP-lowering performance of...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Optical/Ophthalmic Glaukos Source Type: news